期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 61, 期 12, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01183-17
关键词
AmpC; G183D; Pseudomonas aeruginosa; ceftolozane-tazobactam
资金
- National Institute of Allergy and Infectious Diseases [R01AI090155, R21AI117338]
Ceftolozane-tazobactam is a cephalosporin-beta-lactamase inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including strains that are resistant to other beta-lactams. The emergence of ceftolozane-tazobactam resistance among clinical isolates of P. aeruginosa has rarely been described. Here we characterized ceftolozane-tazobactam-resistant P. aeruginosa strains recovered from a patient who was treated with this agent for 6 weeks for a recurrent wound infection. The results showed that the resistance was mediated by a single AmpC structural mutation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据